Brickell Piotroski F Score

BBI
 Stock
  

USD 3.57  0.41  10.30%   

This module uses fundamental data of Brickell Biotech to approximate its Piotroski F score. Brickell Biotech F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Brickell Biotech. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Brickell Biotech financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to Brickell Biotech Altman Z Score, Brickell Biotech Correlation, Brickell Biotech Valuation, as well as analyze Brickell Biotech Alpha and Beta and Brickell Biotech Hype Analysis.
  
Refresh
Brickell Biotech Issuance Repayment of Debt Securities is most likely to in the upcoming years. The last year's value of Issuance Repayment of Debt Securities was reported at 502,550. The current Debt to Equity Ratio is estimated to increase to 0.23, while Debt Non Current is projected to decrease to roughly 151.8 K. Brickell Biotech Accrued Expenses Turnover is most likely to slightly decrease in the upcoming years. The last year's value of Accrued Expenses Turnover was reported at 0.52. The current Cash and Equivalents Turnover is estimated to increase to 0.08, while Operating Margin is projected to decrease to (120.19) .
At this time, it appears that Brickell Biotech's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginNo ChangeFocus

Brickell Biotech Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Brickell Biotech is to make sure Brickell is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Brickell Biotech's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Brickell Biotech's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares86.7 M80.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted86.7 M80.3 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations(37.1 M)(36.1 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets37.2 M29.7 M
Significantly Up
Decreasing
Slightly volatile
Total Liabilities4.9 M4.8 M
Fairly Up
Increasing
Very volatile
Current Assets35 M29.6 M
Fairly Up
Decreasing
Slightly volatile
Current Liabilities7.3 M4.8 M
Way Up
Increasing
Stable
Total Debt403.6 K393.3 K
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.931.15
Significantly Down
Increasing
Slightly volatile
Asset Turnover0.01330.013
Fairly Up
Decreasing
Slightly volatile

Brickell Biotech F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Brickell Biotech's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Brickell Biotech in a much-optimized way.

About Brickell Biotech Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Weighted Average Shares

86.66 Million

Brickell Biotech Weighted Average Shares is most likely to increase significantly in the upcoming years. The last year's value of Weighted Average Shares was reported at 80.32 Million

Brickell Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brickell Biotech from analyzing Brickell Biotech's financial statements. These drivers represent accounts that assess Brickell Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brickell Biotech's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(122.58 K)(175.13 K)(541.8 K)(1.59 M)(1.83 M)(1.88 M)
Revenue Per Employee198.51 K186.74 K54.07 K527.8 K475.02 K512.52 K
Average Assets58.08 M45.63 M34.66 M25.13 M30.46 M39.21 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(12.17 M)(8.1 M)(21.75 M)(20.9 M)(39.38 M)(40.42 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(12.17 M)(8.1 M)(21.75 M)(20.9 M)(39.38 M)(40.42 M)
Earnings before Tax(12.96 M)(9.24 M)(23.88 M)(20.91 M)(39.47 M)(40.51 M)
Average Equity45.92 M23.07 M27.82 M17.91 M24.09 M32.33 M
Enterprise Value12.67 M13.45 M4.59 M22.04 M4.97 M5.1 M
Free Cash Flow(8.68 M)3.96 M(35.99 M)(20.06 M)(36.18 M)(37.14 M)
Invested Capital37.84 M(15.21 M)488 K(2.4 M)(1.98 M)(2.03 M)
Invested Capital Average32.37 M28.85 M20.09 M(1.32 M)(2.55 M)(2.62 M)
Market Capitalization23.07 M25.74 M11.72 M41.77 M26.33 M27.03 M
Tangible Asset Value79.79 M8.31 M18.14 M33.63 M29.72 M36.69 M
Working Capital59.4 M(11.82 M)7.47 M27.18 M24.79 M28.97 M

About Brickell Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brickell Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brickell Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brickell Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Brickell Biotech Investors Sentiment

The influence of Brickell Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brickell. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Brickell Biotech's public news can be used to forecast risks associated with investment in Brickell. The trend in average sentiment can be used to explain how an investor holding Brickell can time the market purely based on public headlines and social activities around Brickell Biotech. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Brickell Biotech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Brickell Biotech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Brickell Biotech's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Brickell Biotech.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brickell Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brickell Biotech's short interest history, or implied volatility extrapolated from Brickell Biotech options trading.

Current Sentiment - BBI

Brickell Biotech Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brickell Biotech. What is your opinion about investing in Brickell Biotech? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Brickell Biotech Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Brickell Biotech Altman Z Score, Brickell Biotech Correlation, Brickell Biotech Valuation, as well as analyze Brickell Biotech Alpha and Beta and Brickell Biotech Hype Analysis. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
11.7 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.